RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David A. Foster to Neoplasms

This is a "connection" page, showing publications David A. Foster has written about Neoplasms.
Connection Strength

2.587
  1. Hatipoglu A, Menon D, Levy T, Frias MA, Foster DA. Inhibiting glutamine utilization creates a synthetic lethality for suppression of ATP citrate lyase in KRas-driven cancer cells. PLoS One. 2022; 17(10):e0276579.
    View in: PubMed
    Score: 0.422
  2. Bernfeld E, Foster DA. Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells. Trends Endocrinol Metab. 2019 06; 30(6):357-368.
    View in: PubMed
    Score: 0.332
  3. Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA. The Enigma of Rapamycin Dosage. Mol Cancer Ther. 2016 Mar; 15(3):347-53.
    View in: PubMed
    Score: 0.266
  4. Mukhopadhyay S, Saqcena M, Chatterjee A, Garcia A, Frias MA, Foster DA. Reciprocal regulation of AMP-activated protein kinase and phospholipase D. J Biol Chem. 2015 Mar 13; 290(11):6986-93.
    View in: PubMed
    Score: 0.247
  5. Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, Foster DA. 5-Aminoimidazole-4-carboxamide-1-?-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle. 2015; 14(20):3331-9.
    View in: PubMed
    Score: 0.246
  6. Toschi A, Lee E, Thompson S, Gadir N, Yellen P, Drain CM, Ohh M, Foster DA. Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett. 2010 Dec 18; 299(1):72-9.
    View in: PubMed
    Score: 0.186
  7. Foster DA, Darnell JE. Obituary: Hidesaburo Hanafusa (1929-2009). Nature. 2009 Apr 09; 458(7239):718.
    View in: PubMed
    Score: 0.165
  8. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009 Apr 01; 8(7):1026-9.
    View in: PubMed
    Score: 0.165
  9. Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta. 2009 Sep; 1791(9):949-55.
    View in: PubMed
    Score: 0.164
  10. Foster DA. Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Expert Rev Anticancer Ther. 2004 Aug; 4(4):691-701.
    View in: PubMed
    Score: 0.119
  11. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003 Sep; 1(11):789-800.
    View in: PubMed
    Score: 0.112
  12. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA. Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS One. 2013; 8(8):e74157.
    View in: PubMed
    Score: 0.056
  13. Garcia A, Zheng Y, Zhao C, Toschi A, Fan J, Shraibman N, Brown HA, Bar-Sagi D, Foster DA, Arbiser JL. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res. 2008 Jul 01; 14(13):4267-74.
    View in: PubMed
    Score: 0.039
  14. Shi M, Zheng Y, Garcia A, Xu L, Foster DA. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett. 2007 Dec 18; 258(2):268-75.
    View in: PubMed
    Score: 0.037
  15. Jackson DN, Foster DA. The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival. FASEB J. 2004 Apr; 18(6):627-36.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support